Have a personal or library account? Click to login
Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer Cover

Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

Forum of Clinical Oncology
Volume 7 (2016): Issue 1 (March 2016)
By: Nikolaos F. Pistamaltzian,  Sonia A. Perez and  Constantin N. Baxevanis  
Open Access
|Sep 2016

Figures & Tables

Clinical trials using various therapeutic vaccines_

STUDY NAMETARGET ANTIGENVACCINE NAME/TYPECANCER
IMPACTPAPMo/DCsPAP-GM-CSFmCRPC
PROSPECTPSAPSA-TRICOMmCRPC
StimuvaxMUC1BLPD25NSCLC
PANVACMUC1/CEADCsPSA-TRICOMColorectal
GVAXmultipleT47D&SKBR3 linesBreast
DERMAMAGE-A3Rec ProteinMelanoma
MAGRITMAGE-A3Rec ProteinNSCLC
IMPRINT11 tumour peptidessolubleRenal
TG4010MUC1MVA MUC-1-IL-2Prostate NSCLC
CDX110EGFRvIIISoluble 13-merGlioblastoma
DOI: https://doi.org/10.1515/fco-2016-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 4 - 16
Submitted on: Feb 24, 2016
Accepted on: Aug 4, 2016
Published on: Sep 17, 2016
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Cancer immunotherapy,
Tumor infiltrating lymphocytes,
Immunoscore,
Cancer vaccines,
Checkpoint inhibitors
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2016 Nikolaos F. Pistamaltzian, Sonia A. Perez, Constantin N. Baxevanis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 7 (2016): Issue 1 (March 2016)Next article